Humana (HUM) reaffirm its guidance
Tweet
Share
E-mail
Get Alerts HUM Hot Sheet
Price: $388.90 --0%
EPS Growth %: +15.3%
Financial Fact:
Services: 227M
Today's EPS Names:
DTGI, CRMT, STZ, More
EPS Growth %: +15.3%
Financial Fact:
Services: 227M
Today's EPS Names:
DTGI, CRMT, STZ, More
Join SI Premium – FREE
Humana (NYSE: HUM) disclosed:
Members of Humana Inc.’s (the “Company”) senior management team are scheduled to meet with investors and analysts at various meetings between March 3, 2025 and March 31, 2025. During these meetings, the Company intends to reaffirm its guidance of approximately $15.88 in diluted earnings per common share (“EPS”) or approximately $16.25 in adjusted earnings per common share (“Adjusted EPS”), in each case for the year ending December 31, 2025 (“FY 2025”). This guidance is consistent with the guidance issued in Humana’s press release dated February 11, 2025.
The Company has included Adjusted EPS in this current report, a financial measure that is not in accordance with Generally Accepted Accounting Principles (“GAAP”). Management believes that this measure, when presented in conjunction with the comparable measure of GAAP EPS, provides a comprehensive perspective to more accurately compare and analyze the Company’s core operating performance over time. Consequently, management uses Adjusted EPS as a consistent and uniform indicator of the Company’s core business operations from period to period, as well as for planning and decision-making purposes and in determination of incentive compensation. Adjusted EPS should be considered in addition to, but not as a substitute for, or superior to, GAAP EPS. A reconciliation of GAAP EPS to Adjusted EPS follows:
| Diluted earnings per common share | FY 2025 Guidance | ||||
| GAAP | approximately $15.88 | ||||
| Amortization of identifiable intangibles | 0.49 | ||||
| Cumulative net tax impact of non-GAAP adjustments | (0.12) | ||||
| Adjusted (non-GAAP) – FY 2025 projected | approximately $16.25 | ||||
Cautionary Statement
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- UnitedHealth Group (UNH) PT Raised to $468 at Morgan Stanley
- AeroVironment (AVAV) Tops Q4 EPS by 36c
- Canaccord Reiterates Buy Rating on Neurogene (NGNE)
Create E-mail Alert Related Categories
Corporate News, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
